Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Advanced Hepatocellular Carcinoma (HCC) · Metastatic Liver Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (Zhen J Peng, Phd) · Zhen-Peng@beijing-biotech.com · +86 13076790039

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma · Liver Cancer

Abroad (travel likely)RecruitingPHASE1

Seoul, South Korea · Seoul, South Korea

HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Lanzhou, China · Guangzhou, China

A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE2

Shanghai, China